Research Article, J Otol Rhinol Vol: 3 Issue: 4
Efficacy and Safety of Sequential Chemoradiation with Docetaxel, Cisplatin, and 5-Fluorouracil (TPF) in Treating the Patients with Squamous Cell Carcinoma of the Hypopharynx: A Phase II Clinical Trial
| Niloofar Ahmadloo1, Sayed Hasan Hamedi2, Samira Razzaghi2, Bijan Khademi3,4, Seyed Basir Hashemi4, Leila Moaddabshoar2, Ahmad Mosalaei1,3, Mansour Ansari1, Shapour Omidvari1,Hamid Nasrolahi1 and Mohammad Mohammadianpanah5* | |
| 1Department of Radiation Oncology, Namazi Hospital, Shiraz University of Medical Sciences, Shiraz, Iran | |
| 2Student Research Committee, Department of Radiation Oncology, Shiraz University of Medical Sciences, Shiraz, Iran | |
| 3Shiraz institute for Cancer Research, Shiraz University of Medical Sciences,Shiraz, Iran | |
| 4Department of Otolaryngology, Head and Neck Surgery, Khalili Hospital,Shiraz University of Medical Sciences, Shiraz, Iran | |
| 5Colorectal Research Center, Shiraz University of Medical Sciences, Shiraz,Iran | |
| Corresponding author : Mohammad Mohammadianpanah Colorectal Research Center, Department of Radiation Oncology, Namazi Hospital, Shiraz University of Medical Sciences, Shiraz 71936-11351, Iran Tel: 0098-711-6125170; Fax: 0098-711-6474320 E-mail: mohpanah@gmail.com |
|
| Received: April 07, 2014 Accepted: June 03, 2014 Published: June 15, 2014 | |
| Citation: Ahmadloo N, Hamedi SH, Razzaghi S, Khademi B, Hashemi SB (2014) Efficacy and Safety of Sequential Chemoradiation with Docetaxel, Cisplatin, and 5-Fluorouracil (TPF) in Treating the Patients with Squamous Cell Carcinoma of the Hypopharynx: A Phase II Clinical Trial. J Otol Rhinol 3:4. doi:10.4172/2324-8785.1000160 |
Abstract
Efficacy and Safety of Sequential Chemoradiation with Docetaxel, Cisplatin, and 5-Fluorouracil (TPF) in Treating the Patients with Squamous Cell Carcinoma of the Hypopharynx: A Phase II Clinical Trial
Background: The present study aimed to investigate the efficacy and safety of sequential chemoradiation with docetaxel, cisplatin, and 5-Fluorouracil (TPF) in the patients with Squamous Cell Carcinoma (SCC) of the hypopharynx.
Patients and Methods: In this single arm phase II clinical trial, eligible patients had to have newly diagnosed, locally advanced (T3-T4 and/or N2-N3, M0) hypopharyngeal SCC, no prior therapy, Eastern Cooperative Oncology Group performance scale ≤1, and normal or acceptable organ function. The patients were assigned to receive three cycles of 3-weekly induction chemotherapy in an outpatient setting with docetaxel 75 mg/m2, cisplatin 75 mg/m2, and 5-fluorouracil 750 mg/m2 × 3 days of 8-hour infusion, followed by definite radiotherapy with a total dose of 70 Gy with concurrent cisplatin 30 mg/m2 weekly. Tumor response rates and treatmentrelated toxicity were the primary and secondary study endpoints, respectively.
